UT Southwestern Harold C. Simmons Comprehensive Cancer Center | Strategic Alliance Partners

Larry Anderson, MD, PhD, discusses recent FDA approvals in multiple myeloma.

Srikanth Nagalla, MD, discusses the utility of direct oral anticoagulants in patients with a myeloproliferative neoplasm–associated venous thromboembolism.

I. Alex Bowman, MD, discusses the rationale for an exploratory clinical trial of radio-labeled 89Zr-atezolizumab PET/CT scans in renal cell carcinoma.

Hans Hammers, MD, PhD, associate professor of internal medicine, Division of Hematology-Oncology, UT Southwestern Medical Center, discusses the challenges with using CAR T-cell therapy in renal cell carcinoma.

A new molecular mechanism discovered by UT Southwestern researchers indicates that drugs currently used to treat less than 10 percent of breast cancer patients could have broader effectiveness in treating all cancers where the drugs are used, including ovarian and prostate cancers.

Amit G. Singal, MD, associate professor, UT Southwestern Medical Center, discusses the FDA approval of cabozantinib (Cabometyx) for patients with hepatocellular carcinoma (HCC) who previously received sorafenib (Nexavar).

Amit G. Singal, MD, associate professor, UT Southwestern Medical Center, discusses the potential of immunotherapy in the treatment landscape of hepatocellular carcinoma.

Amit G. Singal, MD, associate professor, UT Southwestern Medical Center, discusses recent clinical trials in hepatocellular carcinoma.

Amit G. Singal, MD, associate professor, UT Southwestern Medical Center, discusses emerging systemic therapies in hepatocellular carcinoma.

Hak Choy, MD, Nancy B. & Jake L. Hamon Distinguished Chair in Therapeutic Oncology Research, Department of Radiation Oncology, UT Southwestern Medical Center, discuses therapy for patients with oligometastatic lung cancer.

Amit G. Singal, MD, discusses the evolving armamentarium of treatment options for patients with hepatocellular carcinoma.

Amit G. Singal, MD, associate professor, UT Southwestern Medical Center, discusses sequencing therapy for patients with hepatocellular carcinoma.

Dr. Carlos L. Arteaga will be the new Director of the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern.

Raquibul Hannan, MD, PhD, discusses the benefits of using stereotactic radiation for patients with renal cell carcinoma and highlights ongoing trials examining the modality.

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the combination of vaccines and immune checkpoint inhibitors in the treatment of patients with renal cell carcinoma.

Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses a mature data set regarding nivolumab and ipilimumab in the treatment of patients with renal cell carcinoma.

Vitaly Margulis, MD, assistant professor of Urologic Oncology, UT Southwestern Medical Center, discusses 2 different approaches to administering adjuvant therapy for patients with renal cell carcinoma.

Stereotactic ablative radiosurgery, which is administered in far fewer but larger doses than conventional radiotherapy, has the potential to benefit a substantial proportion of patients with low-, intermediate-, and potentially even high-risk prostate cancers.

Udit Verma, MD, associate professor of Internal Medicine in Hematology/Oncology, UT Southwestern Medical Center, discusses a subgroup analysis of the CONSIGN study, which examined regorafenib (Stivarga) in patients with metastatic colorectal cancer.

David Sher, MD, radiation oncologist, UT Southwestern Medical Center, provides an update on and the basis for ASTRO's Multidisciplinary Head and Neck Cancer Guideline.

A substantial—and potentially growing—proportion of patients with non–small cell lung cancer are people who never, or only rarely, smoked.

John Minna, MD, Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology, Sarah M. and Charles E. Seay Distinguished Chair in Cancer Research, Hamon Center for Therapeutic Oncology, Internal Medicine, Pharmacology, UT Southwestern Medical Center, discusses the roles that both chemotherapy and radiation therapy will continue to have in the treatment of lung cancer.

Prior cancer history should not exclude patients with advanced lung cancer from participating in clinical trials because it does not impact clinical outcomes.